Results 51 to 60 of about 25,067 (205)

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis

BMC Cancer, 2023
Objective To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians.
Xiu Chen, Qinglian Wen, Liqiu Kou, Xiaolu Xie, Jun Li, Yaling Li   +5 more
doaj   +1 more source

Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

Frontiers in Oncology, 2022
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases.
Mohammed Hafiz Uddin, Jun-Ying Zhou, Julio Pimentel, Steve M. Patrick, Steve M. Patrick, Steve M. Patrick, Seongho Kim, Seongho Kim, Malathy P. Shekhar, Malathy P. Shekhar, Malathy P. Shekhar, Gen Sheng Wu, Gen Sheng Wu, Gen Sheng Wu   +13 more
doaj   +1 more source

Olaparib for advanced breast cancer

, 2020
Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared ...
Dieci M. V., Conte P., Guarneri V., Griguolo G., Miglietta F.   +4 more
core   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer

Case Reports in Oncological Medicine, 2018
Olaparib was first FDA approved for use in women with advanced ovarian cancer and germline BRCA mutations. Based on the results of subsequent research, the use of this drug has been expanded to patients with metastatic breast cancer with germline BRCA ...
Megan Wheelden, Leah Cream, Jeffrey Sivik, Mark Robson   +3 more
doaj   +1 more source

HNRNPU K181 Lactylation Drives Cervical Cancer Growth by Upregulating PHGDH and Reprogramming Serine Metabolism

Advanced Science, EarlyView.
Lactate in cervical cancer induces HNRNPU K181 lactylation, opposed by NAA50‐mediated acetylation and suppressed by Pazopanib. This lactylation enhances HNRNPU binding to PHGDH pre‐mRNA exon 1, maintaining exon 1‐containing transcripts and mRNA stability, thereby activating serine metabolism.
Chang Zhang, Qingfei Meng, Hui Jiao, Huixin Liu, Xiangchao Wang, Honglan Zhou, Yishu Wang   +6 more
wiley   +1 more source

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway

Cancer Biology & Therapy
Background Resistance to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) remain a major challenge in ovarian cancer (OC) treatment. However, the underlying mechanism of PARPi resistance is still poorly characterized.
Minxue Gai, Lanlan Zhao, Hongqi Li, Guoyu Jin, Wei Li, Fei Wang, Ming Liu   +6 more
doaj   +1 more source

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib

Journal of Immunology Research, 2022
This project attempts to clarify the expression of MUS81 in castration-resistant prostate cancer (CRPC) and the effect on drug sensitivity to Olaparib.
Lifeng Gong, Yu Tang, Li Jiang, Wei Tang, Shengjun Luo   +4 more
doaj   +1 more source

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors

Advanced Science, EarlyView.
This study presents the first ubiquitin‐specific protease 1 (USP1) allosteric fluoroprobe and fluorescence polarization assay, enabling the differentiation of allosteric and catalytic site inhibitors. Further, a novel class of tetrahydroisoquinoline‐based USP1 inhibitors is designed, with compound 14a (USP1 IC50 = 29.9 nM) showing strong selectivity ...
Jiawei Cheng, Peipei Wang, Pengfei Wang, Jiamin Wang, Baiyang Li, Daqing Fang, Jian He, Xiaobei Hu, Weijuan Kan, Yubo Zhou, Chunpu Li, Jia Li, Hong Liu   +12 more
wiley   +1 more source

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. [PDF]

, 2021
BACKGROUND Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality.
Geyer, Charles E, McFadden, Eleanor, Nowecki, Zbigniew, Korde, Larissa, Arahmani, Amal, Suga, Jennifer M., Costantino, Joseph P., Lakhani, Sunil R., De Laurentiis ,Michelino, Campbell, Christine, Garber, Judy E, Shao, Zhimin, Steger, Guenther G, Tutt, Andrew N J, Hollingsworth, Simon S.J., Huzarski, Tomasz, Karantza, Vassiliki, Gelmon, Karen A, Korde, Larissa A., Viale, Giuseppe, Steger, Guenther G., Lakhani, Sunil R, Geyer, Charles E., Tutt, Andrew M, Ganz, Patricia A, Tutt, Andrew NJ, Lucas, Peter C., Fielding, Anitra, Kaufman, Bella, Pippas, Andrew W., Balmaña, Judith, McConnell, Robin, Gelber, Richard D, Tutt, Andrew N.J., Suga, Jennifer Marie, Wolmark, Norman, Rastogi, Priya, de Azambuja, Evandro, Domchek, Susan M, Domchek, Susan S.M., Gelber, Richard D., Domchek, Susan M., Lakhani, Sunil S.R., Pippas, Andrew A.W., Piccart-Gebhart, Martine, Gelmon, Karen K.A., Lucas, Peter C, Korde, Larissa A, Senkus, Elżbieta, Suga, Jennifer M, Fumagalli, Debora, Linderholm, Barbro, Steger, Günther G.G., Pippas, Andrew W, Hollingsworth, Simon J, Gelber, Richard, Ganz, Patricia A., Bandos, Hanna, Yothers, Greg, Lucas, Peter P.C., Gelmon, Karen A., Baker, Nigel, Loibl, Sibylle, Linderholm, Barbro B.K., Piccart, Martine, Garber, Judy Ellen, Geyer Jr. Charles C.E., Hollingsworth, Simon J., Garber, Judy E., Schmutzler, Rita, Costantino, Joseph P, nella lista dei Collaborators   +71 more
core   +1 more source